0001299130-21-000053.txt : 20210217
0001299130-21-000053.hdr.sgml : 20210217
20210217211735
ACCESSION NUMBER: 0001299130-21-000053
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210212
FILED AS OF DATE: 20210217
DATE AS OF CHANGE: 20210217
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: LIVINGSTON RANDALL S
CENTRAL INDEX KEY: 0001235118
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-34899
FILM NUMBER: 21647403
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
CENTRAL INDEX KEY: 0001299130
STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826]
IRS NUMBER: 161590339
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1305 O'BRIEN DRIVE
CITY: MENLO PARK
STATE: CA
ZIP: 94025
BUSINESS PHONE: 650-521-8000
MAIL ADDRESS:
STREET 1: 1305 O'BRIEN DRIVE
CITY: MENLO PARK
STATE: CA
ZIP: 94025
FORMER COMPANY:
FORMER CONFORMED NAME: PACIFIC BIOSCIENCES OF CALIFORNIA INC
DATE OF NAME CHANGE: 20050829
FORMER COMPANY:
FORMER CONFORMED NAME: NANOFLUIDICS INC
DATE OF NAME CHANGE: 20040729
4
1
certent-form4.xml
PRIMARY DOCUMENT
X0306
4
2021-02-12
0001299130
PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
PACB
0001235118
LIVINGSTON RANDALL S
PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
1305 O'BRIEN DRIVE
MENLO PARK
CA
94025
1
0
0
0
Common Stock
2021-02-12
4
M
0
17500
10.58
A
17500
D
Common Stock
2021-02-12
4
M
0
25000
1.83
A
42500
D
Common Stock
2021-02-12
4
M
0
25000
2.54
A
67500
D
Common Stock
2021-02-12
4
S
0
67500
48.066
D
0
D
Stock Option (right to buy)
10.58
2021-02-12
4
M
0
17500
0
D
2021-06-23
Common Stock
17500
0
D
Stock Option (right to buy)
1.83
2021-02-12
4
M
0
25000
0
D
2022-06-13
Common Stock
25000
0
D
Stock Option (right to buy)
2.54
2021-02-12
4
M
0
25000
0
D
2023-05-21
Common Stock
25000
0
D
This sale price represents the weighted average sale price of the shares sold ranging from $48.00 to $48.70 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
The shares subject to the option are fully vested and exercisable.
/s/ Brett Atkins, Attorney-in fact
2021-02-17